ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib

被引：3
|
作者：
Piotrowska, Z. [1 ]
Ahn, M-J. [2 ]
Pang, Y-K. [3 ]
How, S. H. [4 ]
Sang-We, K. [5 ]
Voon, P. J. [6 ]
Cortinovis, D. L. [7 ]
Carpeno, J. De Castro [8 ]
Tiseo, M. [9 ,10 ]
Abreu, D. Rodriguez [11 ]
Ramalingam, S. S. [12 ]
Li, J. [13 ]
Servidio, L. [13 ]
Sadow, S. [14 ]
Hartmaier, R. J. [15 ]
Cho, B. C. [16 ]
机构：
[1] Massachusetts Gen Hosp, Dept Med, Boston, MA USA
[2] Sungkyunkwan Univ, Dept Hematol & Oncol, Samsung Med Ctr, Sch Med, Seoul, South Korea
[3] Univ Malaya, Dept Med, Fac Med, Kuala Lumpur, Malaysia
[4] Int Islamic Univ Malaysia, Dept Med, Kulliyyah Med, Kuantan, Malaysia
[5] Asan Med Ctr, Dept Oncol, Seoul, South Korea
[6] Hosp Umum Sarawak, Dept Radiotherapy & Oncol, Kuching, Malaysia
[7] San Gerardo Hosp, Oncol Unit, Monza, Italy
[8] Hosp Univ La Paz, Dept Med Oncol, IdiPAZ, Madrid, Spain
[9] Univ Parma, Dept Med & Surg, Parma, Italy
[10] Univ Hosp Parma, Med Oncol Unit, Parma, Italy
[11] Gran Canaria Univ Hosp, Dept Med Oncol, Las Palmas Gran Canaria, Canary Islands, Spain
[12] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA
[13] AstraZeneca, Oncol Business Unit, Global Med Affairs, Gaithersburg, MD USA
[14] AstraZeneca, Biometr & Informat Sci, Gaithersburg, MD USA
[15] AstraZeneca Oncol R&D, Translat Med, Boston, MA USA
[16] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.398
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
360P
引用
收藏
页码：S1581 / S1582
页数：2
相关论文
共 50 条
  • [41] Osimertinib in Epidermal Growth Factor Receptor-Mutated (EGFR plus ) Metastatic Non-Small-Cell Lung Cancer (NSCLC) Real-World Patients
    Tavara, B.
    Lopez, L.
    Medina, S.
    Garrido, M. L.
    Lopez, A.
    Lopez, M.
    Vallejo Pascual, M. E.
    Tain, P. Diz
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S642 - S642
  • [42] Overall Response to First-Line Tyrosine Kinase Inhibitor and Second-Line Chemotherapy Is Predictive of Survival Outcome in Epidermal Growth Factor Receptor-Mutated Adenocarcinoma
    Kuo, Scott Chih-Hsi
    Hsu, Ping-Chih
    Chen, Chih-Hung
    Yu, Chih-Teng
    Wang, Chih-Liang
    Chung, Fu-Tsai
    Lin, Shu-Min
    Lo, Yu-Lun
    Chen, Tse-Ching
    Liu, Chien-Ying
    Yang, Cheng-Ta
    CHEMOTHERAPY, 2014, 60 (03) : 201 - 210
  • [43] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes
    Planchard, D.
    Boyer, M.
    Lee, J-S.
    Dechaphunkul, A.
    Cheema, P.
    Takahashi, T.
    Todd, A.
    McKeown, A.
    Rukazenkov, Y.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2018, 29 : 169 - 169
  • [44] Real-world outcomes of first-line osimertinib for EGFR mutated advanced NSCLC patients in China: Interim analysis of the FLOURISH study
    Zhou, J.
    Zhou, J.
    Zheng, J.
    Wang, K.
    Tang, K.
    Lu, D.
    Cui, J.
    Zhu, D.
    Wang, Y.
    Zhao, Y.
    Xing, L.
    Ding, L.
    Shi, X.
    Shen, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1065 - S1065
  • [45] Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
    Fujimoto, D.
    Takiguchi, Y.
    Matsumoto, S.
    Yamamoto, N.
    Saito, G.
    Nishimura, Y.
    Sugiyama, S.
    Oku, A.
    Karia, P.
    Antunes, L.
    Chapaneri, J.
    Salomonsen, R. J-B.
    Martin, E.
    Okhuoya, P.
    Muto, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1657 - S1658
  • [46] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes
    Planchard, D.
    Boyer, M.
    Lee, J-S.
    Dechaphunkul, A.
    Cheema, P.
    Takahashi, T.
    Todd, A.
    McKeown, A.
    Rukazenkov, Y.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S72 - S73
  • [47] MOLECULAR PROFILING OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) PATHWAY IN THE MANAGEMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS)
    Nuzzo, C.
    Sperduti, I.
    Marchetti, A.
    Cianciulli, A. M.
    Mottolese, M.
    Buttitta, F.
    Visca, P.
    Cecere, F. L.
    Cognetti, F.
    Milella, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 105 - 105
  • [48] Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
    Kilickap, S.
    Sezer, A.
    Gumus, M.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    Turk, H. M.
    Cicin, I.
    Bentsion, D.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Li, S.
    Lee, S.
    Makharadze, T.
    Paydas, S.
    Nechaeva, M.
    Seebach, F.
    Weinreich, D. M.
    Yancopoulos, G. D.
    Gullo, G.
    Lowy, I.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S101 - S101
  • [49] Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment
    Wang, Tso-Fu
    Chu, Sung-Chao
    Lee, Jen-Jyh
    Yang, Gee-Gwo
    Huang, Wei-Han
    Chang, En-Ting
    Low, Tissot
    Wu, Yi-Feng
    Kao, Ruey-Ho
    Lin, Chih-Bin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (04) : 304 - 313
  • [50] Efficacy of osimertinib (osi) on (prevention of) bone metastases (mets) and skeletal related events (SREs) in patients (pts) with epidermal growth factor receptor mutated (EGFRm plus ) non-small cell lung cancer (NSCLC)
    Brouns, A.
    Veelen, A. V.
    Veerman, M.
    Steendam, C.
    Dursun, S.
    Croes, S.
    Dingemans, A-M. C.
    Hendriks, L.
    ANNALS OF ONCOLOGY, 2022, 33 : S54 - S54
12345